Ginkgo Bioworks (DNA) Financials

$6.45 -0.47 (-6.75%)

Closing price 05/6/2025 03:59 PM Eastern

Extended Trading

$6.86 +0.40 (+6.23%)

As of 08:03 AM Eastern

Annual Income Statements for Ginkgo Bioworks

This table shows Ginkgo Bioworks' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-2,105	-893	-547
Consolidated Net Income / (Loss)	-2,106	-893	-547
Net Income / (Loss) Continuing Operations	-2,106	-893	-547
Total Pre-Tax Income	-2,121	-893	-548
Total Operating Income	-2,209	-864	-560
Total Gross Profit	273	197	182
Total Revenue	478	251	227
Operating Revenue	478	251	227
Total Cost of Revenue	204	54	45
Operating Cost of Revenue	204	54	45
Total Operating Expenses	2,482	1,062	742
Selling, General & Admin Expense	1,430	385	246
Research & Development Expense	1,053	581	424
Impairment Charge	0.00	96	48
Restructuring Charge	0.00	0.00	24
Total Other Income / (Expense), net	88	-29	12
Interest Expense	0.11	0.09	0.09
Interest & Investment Income	-45	-43	2.77
Other Income / (Expense), net	133	14	9.57
Income Tax Expense	-15	-0.07	-0.48
Net Income / (Loss) Attributable to Noncontrolling Interest	-1.44	0.00	0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.00	0.00	-1.49
Basic Earnings per Share	($50.15)	($18.37)	($10.54)
Weighted Average Basic Shares Outstanding	41.98M	48.61M	51.89M
Diluted Earnings per Share	($50.20)	($18.37)	($10.54)
Weighted Average Diluted Shares Outstanding	42.00M	48.61M	51.89M
Weighted Average Basic & Diluted Shares Outstanding	1.95B	2.15B	58.03M

This table shows Ginkgo Bioworks' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-670	-175	-205	-173	-303	-212	-166	-217	-55	-109
Consolidated Net Income / (Loss)	-670	-173	-205	-173	-303	-212	-166	-217	-56	-108
Net Income / (Loss) Continuing Operations	-670	-173	-205	-173	-303	-212	-166	-217	-56	-108
Total Pre-Tax Income	-670	-188	-205	-173	-303	-212	-166	-217	-57	-108
Total Operating Income	-655	-231	-216	-184	-286	-178	-178	-223	-55	-104
Total Gross Profit	42	68	58	62	49	28	29	42	77	34
Total Revenue	66	98	81	81	55	35	38	56	89	44
Operating Revenue	66	98	81	81	55	35	38	56	89	44
Total Cost of Revenue	25	30	22	18	6.92	6.61	9.20	14	12	9.62
Operating Cost of Revenue	25	30	22	18	6.92	6.61	9.20	14	12	9.62
Total Operating Expenses	697	299	274	247	335	206	207	265	132	138
Selling, General & Admin Expense	435	121	111	102	82	89	70	66	52	57
Research & Development Expense	261	178	163	144	157	117	136	134	77	76
Total Other Income / (Expense), net	-15	43	11	11	-17	-34	12	5.95	-1.57	-4.25
Interest & Investment Income	-8.48	17	-7.82	-2.19	-36	3.58	-2.54	-6.83	-4.67	17
Other Income / (Expense), net	-13	35	4.13	-1.26	4.78	6.65	2.96	2.47	3.10	1.05
Income Tax Expense	-0.03	-15	0.08	0.07	-0.02	-0.20	0.03	0.19	-0.38	-0.33
Basic Earnings per Share	($0.41)	($4.18)	($0.11)	($0.09)	($6.21)	($4.35)	($0.08)	($0.11)	($1.08)	($2.10)
Weighted Average Basic Shares Outstanding	1.63B	41.98M	1.91B	1.93B	48.77M	48.61M	2.00B	2.05B	52.24M	51.89M
Diluted Earnings per Share	($0.41)	($4.18)	($0.11)	($0.09)	($6.21)	($4.35)	($0.08)	($0.11)	($1.08)	($2.10)
Weighted Average Diluted Shares Outstanding	1.63B	42.00M	1.92B	1.93B	48.77M	48.61M	2.01B	2.06B	52.25M	51.89M
Basic & Diluted Earnings per Share	-	($4.18)	-	-	-	($4.35)	-	-	-	($2.10)
Weighted Average Basic & Diluted Shares Outstanding	1.94B	1.95B	2.09B	1.98B	2.12B	2.15B	2.21B	2.22B	57.48M	58.03M

This table details how cash moves in and out of Ginkgo Bioworks' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-223	-380	-384
Net Cash From Operating Activities	-252	-296	-320
Net Cash From Continuing Operating Activities	-252	-296	-320
Net Income / (Loss) Continuing Operations	-2,106	-893	-547
Consolidated Net Income / (Loss)	-2,106	-893	-547
Depreciation Expense	43	71	63
Non-Cash Adjustments To Reconcile Net Income	1,878	498	275
Changes in Operating Assets and Liabilities, net	-66	29	-111
Net Cash From Investing Activities	-67	-81	-62
Net Cash From Continuing Investing Activities	-67	-81	-62
Purchase of Property, Plant & Equipment	-52	-41	-63
Acquisitions	75	0.00	-5.40
Purchase of Investments	-59	-43	0.00
Sale of Property, Plant & Equipment	0.00	4.43	0.65
Sale and/or Maturity of Investments	10	0.00	4.52
Other Investing Activities, net	-40	-1.34	0.54
Net Cash From Financing Activities	95	-3.22	-1.74
Net Cash From Continuing Financing Activities	95	-3.22	-1.74
Repurchase of Common Equity	-1.47	-0.58	-0.00
Issuance of Common Equity	99	0.00	0.00
Other Financing Activities, net	-2.50	-2.64	-1.74
Effect of Exchange Rate Changes	0.91	-0.59	-0.28

This table details how cash moves in and out of Ginkgo Bioworks' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-75	24	-111	-87	-77	-105	-102	-111	-114	-56
Net Cash From Operating Activities	-28	-105	-91	-74	-74	-58	-89	-84	-104	-42
Net Cash From Continuing Operating Activities	-28	-105	-91	-74	-74	-58	-89	-84	-104	-42
Net Income / (Loss) Continuing Operations	-670	-173	-205	-173	-303	-212	-166	-217	-56	-108
Consolidated Net Income / (Loss)	-670	-173	-205	-173	-303	-212	-166	-217	-56	-108
Depreciation Expense	8.92	16	19	18	21	13	13	17	17	16
Non-Cash Adjustments To Reconcile Net Income	593	90	91	92	214	101	64	121	37	53
Changes in Operating Assets and Liabilities, net	41	-37	4.00	-10	-5.24	40	-0.61	-5.28	-101	-3.48
Net Cash From Investing Activities	-46	30	-19	-11	-3.38	-47	-12	-27	-10	-13
Net Cash From Continuing Investing Activities	-59	30	-19	-11	-3.38	-47	-12	-27	-10	-13
Purchase of Property, Plant & Equipment	-13	-26	-19	-14	-4.38	-3.45	-6.71	-27	-15	-14
Sale of Property, Plant & Equipment	0.11	-0.11	-	-	0.07	1.43	-	-	0.40	0.06
Sale and/or Maturity of Investments	-	-	-	-	-	-	-	-	-	0.57
Net Cash From Financing Activities	-0.39	98	-0.89	-1.38	-0.32	-0.63	-0.85	-0.23	-0.47	-0.20
Net Cash From Continuing Financing Activities	-0.39	98	-0.89	-1.38	-0.32	-0.63	-0.85	-0.23	-0.47	-0.20
Other Financing Activities, net	-0.30	-1.07	-0.31	-1.36	-0.31	-0.66	-0.85	-0.23	-0.46	-0.20
Effect of Exchange Rate Changes	-0.09	1.10	-0.03	-0.47	-0.20	0.10	-0.16	-0.02	-0.04	-0.07

This table presents Ginkgo Bioworks' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	2,539	1,665	1,377
Total Current Assets	1,450	1,002	603
Cash & Equivalents	1,316	944	562
Accounts Receivable	82	18	22
Prepaid Expenses	52	40	19
Plant, Property, & Equipment, net	315	188	204
Total Noncurrent Assets	774	475	571
Long-Term Investments	114	79	49
Goodwill	60	49	0.00
Intangible Assets	111	83	73
Other Noncurrent Operating Assets	489	265	450
Total Liabilities & Shareholders' Equity	2,539	1,665	1,377
Total Liabilities	803	568	661
Total Current Liabilities	173	164	107
Accounts Payable	10	9.32	14
Accrued Expenses	115	110	65
Current Deferred Revenue	48	44	28
Total Noncurrent Liabilities	630	404	554
Noncurrent Deferred Revenue	175	158	99
Other Noncurrent Operating Liabilities	455	246	455
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,736	1,097	716
Total Preferred & Common Equity	1,736	1,097	716
Preferred Stock	0.00	0.00	0.00
Total Common Equity	1,736	1,097	716
Common Stock	6,137	6,386	6,555
Retained Earnings	-4,398	-5,291	-5,838
Accumulated Other Comprehensive Income / (Loss)	-2.63	1.48	-1.81

This table presents Ginkgo Bioworks' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,871	2,417	2,292	2,026	1,582	1,625	1,481
Total Current Assets	1,462	1,327	1,223	1,142	903	783	662
Cash & Equivalents	1,303	1,206	1,106	1,049	840	730	616
Accounts Receivable	116	85	69	63	25	19	24
Prepaid Expenses	38	34	48	29	38	34	22
Plant, Property, & Equipment, net	188	314	294	202	196	211	211
Total Noncurrent Assets	221	776	774	683	483	631	607
Long-Term Investments	4.14	1.19	1.12	86	76	62	62
Goodwill	29	59	59	58	48	0.00	0.00
Intangible Assets	48	109	105	100	77	91	80
Other Noncurrent Operating Assets	140	607	609	439	281	478	466
Total Liabilities & Shareholders' Equity	1,871	2,417	2,292	2,026	1,582	1,625	1,481
Total Liabilities	431	810	788	774	594	792	683
Total Current Liabilities	125	192	163	168	169	166	114
Accounts Payable	11	22	14	11	27	23	16
Accrued Expenses	73	123	110	115	108	117	76
Current Deferred Revenue	41	48	39	43	34	26	23
Total Noncurrent Liabilities	306	618	625	605	425	626	569
Noncurrent Deferred Revenue	172	175	180	170	166	153	105
Other Noncurrent Operating Liabilities	75	443	445	435	259	473	463
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,440	1,608	1,504	1,253	987	833	798
Total Preferred & Common Equity	1,435	0.00	0.00	1,253	987	833	798
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,435	1,608	1,504	1,253	987	833	798
Common Stock	5,669	6,212	6,281	6,334	6,445	6,508	6,528
Retained Earnings	-4,226	-4,603	-4,776	-5,079	-5,456	-5,674	-5,730
Accumulated Other Comprehensive Income / (Loss)	-7.91	-1.61	-1.30	-2.90	-1.55	-1.72	0.26

This table displays calculated financial ratios and metrics derived from Ginkgo Bioworks' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	52.21%	-47.36%	-9.71%
EBITDA Growth	-18.33%	61.67%	37.51%
EBIT Growth	-18.80%	59.06%	35.28%
NOPAT Growth	-20.81%	60.87%	35.24%
Net Income Growth	-14.69%	57.61%	38.73%
EPS Growth	-14.69%	57.61%	42.62%
Operating Cash Flow Growth	0.64%	-17.17%	-8.15%
Free Cash Flow Firm Growth	-77.67%	80.93%	-13.48%
Invested Capital Growth	399.41%	-75.71%	41.96%
Revenue Q/Q Growth	-9.51%	-20.17%	4.17%
EBITDA Q/Q Growth	40.74%	2.69%	12.83%
EBIT Q/Q Growth	40.11%	2.79%	11.13%
NOPAT Q/Q Growth	39.69%	5.75%	11.75%
Net Income Q/Q Growth	40.47%	-4.52%	16.00%
EPS Q/Q Growth	40.47%	-4.52%	15.27%
Operating Cash Flow Q/Q Growth	19.48%	13.65%	4.60%
Free Cash Flow Firm Q/Q Growth	0.00%	34.19%	5.19%
Invested Capital Q/Q Growth	59.07%	-36.50%	-11.57%
Profitability Metrics	-	-	-
Gross Margin	57.25%	78.52%	80.38%
EBITDA Margin	-425.74%	-310.03%	-214.57%
Operating Margin	-462.41%	-343.76%	-246.54%
EBIT Margin	-434.65%	-338.07%	-242.33%
Profit (Net Income) Margin	-440.93%	-355.08%	-240.94%
Tax Burden Percent	99.29%	99.99%	99.91%
Interest Burden Percent	102.17%	105.04%	99.51%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-1,513.72%	-317.41%	-434.65%
ROIC Less NNEP Spread (ROIC-NNEP)	-1,477.58%	-293.93%	-415.64%
Return on Net Nonoperating Assets (RNNOA)	1,386.20%	254.38%	374.31%
Return on Equity (ROE)	-127.52%	-63.02%	-60.34%
Cash Return on Invested Capital (CROIC)	-637.47%	-195.58%	-469.34%
Operating Return on Assets (OROA)	-90.07%	-40.44%	-36.16%
Return on Assets (ROA)	-91.38%	-42.47%	-35.96%
Return on Common Equity (ROCE)	-125.12%	-63.02%	-60.34%
Return on Equity Simple (ROE_SIMPLE)	-121.32%	-81.38%	-76.39%
Net Operating Profit after Tax (NOPAT)	-1,546	-605	-392
NOPAT Margin	-323.69%	-240.63%	-172.58%
Net Nonoperating Expense Percent (NNEP)	-36.14%	-23.47%	-19.01%
Return On Investment Capital (ROIC_SIMPLE)	-89.06%	-55.15%	-54.72%
Cost of Revenue to Revenue	42.75%	21.48%	19.62%
SG&A Expenses to Revenue	299.31%	153.12%	108.42%
R&D to Revenue	220.35%	230.90%	186.78%
Operating Expenses to Revenue	519.66%	422.28%	326.92%
Earnings before Interest and Taxes (EBIT)	-2,076	-850	-550
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2,034	-780	-487
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.89	3.26	0.79
Price to Tangible Book Value (P/TBV)	2.09	3.71	0.88
Price to Revenue (P/Rev)	6.86	14.24	2.49
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	6.03	34.32	0.00
Enterprise Value to Revenue (EV/Rev)	3.87	10.17	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.94	-0.87	-0.90
Leverage Ratio	1.40	1.48	1.68
Compound Leverage Factor	1.43	1.56	1.67
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-1.88	-1.60	-6.14
Noncontrolling Interest Sharing Ratio	1.88%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	8.38	6.11	5.62
Quick Ratio	8.08	5.87	5.44
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-1,955	-373	-423
Operating Cash Flow to CapEx	-482.48%	-812.42%	-516.35%
Free Cash Flow to Firm to Interest Expense	-18,447.87	-4,009.08	-4,501.04
Operating Cash Flow to Interest Expense	-2,379.23	-3,177.42	-3,399.84
Operating Cash Flow Less CapEx to Interest Expense	-2,872.35	-3,568.53	-4,058.28
Efficiency Ratios	-	-	-
Asset Turnover	0.21	0.12	0.15
Accounts Receivable Turnover	4.46	5.01	11.26
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	2.07	1.00	1.16
Accounts Payable Turnover	21.91	5.46	3.79
Days Sales Outstanding (DSO)	81.76	72.84	32.43
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	16.66	66.82	96.24
Cash Conversion Cycle (CCC)	65.10	6.02	-63.81
Capital & Investment Metrics	-	-	-
Invested Capital	307	75	106
Invested Capital Turnover	4.68	1.32	2.52
Increase / (Decrease) in Invested Capital	409	-232	31
Enterprise Value (EV)	1,849	2,558	-46
Market Capitalization	3,279	3,580	564
Book Value per Share	$0.90	$0.52	$12.46
Tangible Book Value per Share	$0.81	$0.46	$11.20
Total Capital	1,736	1,097	716
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-1,430	-1,023	-610
Capital Expenditures (CapEx)	52	36	62
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-39	-106	-66
Debt-free Net Working Capital (DFNWC)	1,277	838	495
Net Working Capital (NWC)	1,277	838	495
Net Nonoperating Expense (NNE)	560	288	155
Net Nonoperating Obligations (NNO)	-1,430	-1,023	-610
Total Depreciation and Amortization (D&A)	43	71	63
Debt-free, Cash-free Net Working Capital to Revenue	-8.10%	-42.23%	-29.11%
Debt-free Net Working Capital to Revenue	267.34%	333.22%	218.23%
Net Working Capital to Revenue	267.34%	333.22%	218.23%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($50.00)	($18.40)	($10.54)
Adjusted Weighted Average Basic Shares Outstanding	41.98M	48.61M	51.89M
Adjusted Diluted Earnings per Share	($50.00)	($18.40)	($10.54)
Adjusted Weighted Average Diluted Shares Outstanding	42.00M	48.61M	51.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	48.81M	53.81M	58.03M
Normalized Net Operating Profit after Tax (NOPAT)	-1,546	-538	-341
Normalized NOPAT Margin	-323.69%	-213.85%	-150.37%
Pre Tax Income Margin	-444.08%	-355.11%	-241.15%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-19,588.19	-9,140.86	-5,853.04
NOPAT to Interest Expense	-14,587.42	-6,506.28	-4,168.40
EBIT Less CapEx to Interest Expense	-20,081.31	-9,531.97	-6,511.48
NOPAT Less CapEx to Interest Expense	-15,080.54	-6,897.39	-4,826.84
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.07%	-0.07%	0.00%

This table displays calculated financial ratios and metrics derived from Ginkgo Bioworks' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-14.45%	-33.81%	-52.08%	-44.29%	-16.52%	-64.64%	-52.98%	-30.24%	60.65%	26.16%
EBITDA Growth	-1,477.42%	88.59%	66.75%	72.72%	60.47%	11.95%	15.82%	-21.10%	86.59%	45.22%
EBIT Growth	-1,234.38%	87.66%	64.04%	70.29%	57.85%	12.44%	17.28%	-18.91%	81.50%	40.19%
NOPAT Growth	-2,355.53%	86.30%	68.06%	71.57%	56.27%	22.85%	17.49%	-21.07%	80.72%	41.83%
Net Income Growth	-554.39%	89.22%	65.41%	74.15%	54.80%	-22.31%	19.06%	-25.31%	81.38%	49.20%
EPS Growth	-412.50%	89.22%	70.27%	78.05%	54.80%	-22.31%	27.27%	-22.22%	82.61%	51.72%
Operating Cash Flow Growth	-441.76%	36.85%	-355.25%	26.03%	-159.34%	44.68%	1.46%	-14.76%	-40.72%	26.62%
Free Cash Flow Firm Growth	-853.60%	0.00%	-142.69%	-137.17%	83.82%	118.84%	149.84%	168.86%	67.26%	-196.50%
Invested Capital Growth	259.14%	399.41%	185.57%	69.13%	-39.15%	-75.71%	-82.31%	-89.86%	1.94%	41.96%
Revenue Q/Q Growth	-54.09%	48.02%	-17.89%	-0.17%	-31.20%	-37.30%	9.18%	48.13%	58.43%	-50.76%
EBITDA Q/Q Growth	-7.18%	72.67%	-6.93%	12.92%	-55.31%	39.12%	-2.24%	-25.26%	82.80%	-148.76%
EBIT Q/Q Growth	-7.05%	70.69%	-8.06%	12.38%	-51.89%	39.11%	-2.09%	-25.95%	76.37%	-96.83%
NOPAT Q/Q Growth	-1.11%	64.75%	6.55%	14.64%	-55.52%	37.81%	0.06%	-25.25%	75.24%	-87.68%
Net Income Q/Q Growth	0.07%	74.17%	-18.43%	15.44%	-74.76%	30.11%	21.63%	-30.90%	74.03%	-90.65%
EPS Q/Q Growth	0.00%	74.17%	-10.00%	18.18%	-74.76%	30.11%	27.27%	-37.50%	-881.82%	-94.44%
Operating Cash Flow Q/Q Growth	71.47%	-268.57%	13.34%	18.82%	-0.02%	21.37%	-54.34%	5.45%	-22.65%	59.00%
Free Cash Flow Firm Q/Q Growth	-198.65%	26.11%	27.97%	29.21%	57.06%	186.06%	90.50%	-2.20%	-120.42%	-153.65%
Invested Capital Q/Q Growth	-17.78%	59.07%	30.50%	-0.91%	-70.42%	-36.50%	-4.97%	-43.21%	197.47%	-11.57%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	62.87%	69.25%	72.27%	77.54%	87.51%	80.98%	75.75%	75.59%	86.52%	78.06%
EBITDA Margin	-992.71%	-183.31%	-238.72%	-208.22%	-470.05%	-456.43%	-427.41%	-361.43%	-39.23%	-198.20%
Operating Margin	-986.38%	-234.89%	-267.34%	-228.57%	-516.68%	-512.49%	-469.12%	-396.66%	-61.99%	-236.29%
EBIT Margin	-1,006.14%	-199.25%	-262.22%	-230.13%	-508.04%	-493.37%	-461.33%	-392.27%	-58.51%	-233.90%
Profit (Net Income) Margin	-1,009.26%	-176.10%	-253.98%	-215.12%	-546.44%	-609.10%	-437.25%	-386.40%	-63.34%	-245.25%
Tax Burden Percent	100.00%	92.14%	100.04%	100.04%	99.99%	99.91%	100.02%	100.09%	99.34%	99.70%
Interest Burden Percent	100.31%	95.92%	96.82%	93.44%	107.57%	123.57%	94.76%	98.42%	108.97%	105.17%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-10,172.41%	-768.93%	-270.06%	-165.24%	-734.53%	-473.20%	-290.93%	-234.30%	-79.83%	-416.58%
ROIC Less NNEP Spread (ROIC-NNEP)	-10,158.24%	-768.19%	-266.04%	-161.60%	-725.93%	-466.10%	-287.04%	-227.87%	-77.87%	-412.29%
Return on Net Nonoperating Assets (RNNOA)	9,920.15%	720.69%	221.40%	128.38%	642.30%	403.39%	234.93%	185.26%	68.87%	371.29%
Return on Equity (ROE)	-252.26%	-48.25%	-48.66%	-36.86%	-92.23%	-69.82%	-56.01%	-49.04%	-10.96%	-45.28%
Cash Return on Invested Capital (CROIC)	0.00%	-637.47%	-549.37%	-336.54%	-365.27%	-195.58%	-105.77%	-114.15%	-376.63%	-469.34%
Operating Return on Assets (OROA)	-264.17%	-41.29%	-45.71%	-35.00%	-82.13%	-59.01%	-48.15%	-36.92%	-7.27%	-34.91%
Return on Assets (ROA)	-264.99%	-36.49%	-44.27%	-32.72%	-88.33%	-72.85%	-45.64%	-36.37%	-7.87%	-36.60%
Return on Common Equity (ROCE)	-246.36%	-47.34%	-48.15%	-36.48%	-92.05%	-69.82%	-56.01%	-49.04%	-10.96%	-45.28%
Return on Equity Simple (ROE_SIMPLE)	-246.62%	0.00%	0.00%	0.00%	-68.19%	0.00%	-86.48%	-107.76%	-81.61%	0.00%
Net Operating Profit after Tax (NOPAT)	-458	-162	-151	-129	-200	-125	-125	-156	-39	-73
NOPAT Margin	-690.47%	-164.42%	-187.13%	-160.00%	-361.67%	-358.75%	-328.38%	-277.66%	-43.40%	-165.40%
Net Nonoperating Expense Percent (NNEP)	-14.18%	-0.74%	-4.02%	-3.64%	-8.60%	-7.10%	-3.89%	-6.43%	-1.96%	-4.29%
Return On Investment Capital (ROIC_SIMPLE)	-	-9.31%	-	-	-	-11.36%	-	-	-	-10.13%
Cost of Revenue to Revenue	37.13%	30.75%	27.73%	22.46%	12.49%	19.02%	24.25%	24.41%	13.48%	21.94%
SG&A Expenses to Revenue	655.47%	123.50%	138.08%	127.02%	147.98%	256.72%	185.24%	117.93%	58.72%	130.67%
R&D to Revenue	393.78%	180.65%	201.53%	179.08%	282.63%	336.75%	359.63%	238.80%	86.48%	174.19%
Operating Expenses to Revenue	1,049.25%	304.15%	339.61%	306.11%	604.19%	593.47%	544.87%	472.25%	148.52%	314.35%
Earnings before Interest and Taxes (EBIT)	-668	-196	-212	-185	-282	-171	-175	-220	-52	-103
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-659	-180	-193	-168	-261	-159	-162	-203	-35	-87
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.88	1.89	1.62	2.58	2.86	3.26	2.53	0.89	0.57	0.79
Price to Tangible Book Value (P/TBV)	4.10	2.09	1.80	2.90	3.27	3.71	2.90	1.00	0.63	0.88
Price to Revenue (P/Rev)	10.55	6.86	6.66	11.90	11.37	14.24	11.96	4.01	2.08	2.49
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	22.44	6.03	3.47	6.99	20.85	34.32	22.32	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	8.20	3.87	3.56	8.50	7.77	10.17	7.57	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.98	-0.94	-0.83	-0.79	-0.88	-0.87	-0.82	-0.81	-0.88	-0.90
Leverage Ratio	1.32	1.40	1.39	1.40	1.45	1.48	1.54	1.68	1.71	1.68
Compound Leverage Factor	1.32	1.34	1.34	1.30	1.56	1.83	1.46	1.65	1.86	1.76
Debt to Total Capital	3.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	3.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	95.67%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	4.55	0.56	-0.31	0.47	-0.46	-0.25	-1.99	-4.21	-4.54	-5.07
Noncontrolling Interest Sharing Ratio	2.34%	1.88%	1.04%	1.03%	0.19%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.71	8.38	6.92	7.49	6.78	6.11	5.34	4.71	5.79	5.62
Quick Ratio	11.36	8.08	6.73	7.19	6.60	5.87	5.12	4.51	5.59	5.44
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-772	-571	-411	-291	-125	108	205	200	-41	-104
Operating Cash Flow to CapEx	-212.24%	-405.87%	-465.95%	-543.36%	-1,707.71%	-2,865.76%	-1,330.24%	-312.19%	-704.62%	-310.81%
Free Cash Flow to Firm to Interest Expense	0.00	-66.58	0.00	0.00	0.00	2.44	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-12.19	0.00	0.00	0.00	-1.31	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-15.20	0.00	0.00	0.00	-1.36	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.26	0.21	0.17	0.15	0.16	0.12	0.10	0.09	0.12	0.15
Accounts Receivable Turnover	6.34	4.46	3.05	2.67	3.52	5.01	3.82	4.20	5.01	11.26
Inventory Turnover	51.55	0.00	25.19	22.45	26.18	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	3.20	2.07	1.68	1.39	1.62	1.00	0.82	0.73	1.06	1.16
Accounts Payable Turnover	26.11	21.91	4.97	5.76	7.03	5.46	1.68	1.99	3.14	3.79
Days Sales Outstanding (DSO)	57.55	81.76	119.75	136.50	103.65	72.84	95.67	86.93	72.92	32.43
Days Inventory Outstanding (DIO)	7.08	0.00	14.49	16.26	13.94	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	13.98	16.66	73.47	63.34	51.91	66.82	217.07	183.51	116.23	96.24
Cash Conversion Cycle (CCC)	50.66	65.10	60.77	89.42	65.69	6.02	-121.40	-96.58	-43.31	-63.81
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	193	307	400	397	117	75	71	40	120	106
Invested Capital Turnover	14.73	4.68	1.44	1.03	2.03	1.32	0.89	0.84	1.84	2.52
Increase / (Decrease) in Invested Capital	314	409	260	162	-75	-232	-330	-356	2.28	31
Enterprise Value (EV)	4,327	1,849	1,390	2,772	2,446	2,558	1,580	-54	-225	-46
Market Capitalization	5,569	3,279	2,597	3,879	3,582	3,580	2,497	739	453	564
Book Value per Share	$0.88	$0.90	$0.82	$0.72	$0.63	$0.52	$0.46	$0.38	$0.36	$12.46
Tangible Book Value per Share	$0.83	$0.81	$0.74	$0.64	$0.55	$0.46	$0.40	$0.34	$0.32	$11.20
Total Capital	1,500	1,736	1,608	1,504	1,253	1,097	987	833	798	716
Total Debt	60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,247	-1,430	-1,207	-1,107	-1,135	-1,023	-916	-793	-678	-610
Capital Expenditures (CapEx)	13	26	19	14	4.31	2.02	6.71	27	15	14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	35	-39	-70	-46	-76	-106	-106	-113	-68	-66
Debt-free Net Working Capital (DFNWC)	1,337	1,277	1,136	1,060	973	838	734	617	548	495
Net Working Capital (NWC)	1,337	1,277	1,136	1,060	973	838	734	617	548	495
Net Nonoperating Expense (NNE)	212	11	54	44	102	87	41	61	18	35
Net Nonoperating Obligations (NNO)	-1,247	-1,430	-1,207	-1,107	-1,135	-1,023	-916	-793	-678	-610
Total Depreciation and Amortization (D&A)	8.92	16	19	18	21	13	13	17	17	16
Debt-free, Cash-free Net Working Capital to Revenue	6.55%	-8.10%	-18.07%	-14.01%	-24.08%	-42.23%	-51.01%	-61.39%	-31.27%	-29.11%
Debt-free Net Working Capital to Revenue	253.30%	267.34%	291.18%	325.24%	309.03%	333.22%	351.70%	334.83%	251.46%	218.23%
Net Working Capital to Revenue	253.30%	267.34%	291.18%	325.24%	309.03%	333.22%	351.70%	334.83%	251.46%	218.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($16.40)	($167.20)	($4.40)	($3.60)	($6.40)	($174.00)	($3.20)	($4.40)	($1.08)	($2.10)
Adjusted Weighted Average Basic Shares Outstanding	40.77M	1.05M	47.87M	48.34M	48.77M	1.22M	50.11M	51.37M	52.24M	51.89M
Adjusted Diluted Earnings per Share	($16.40)	($167.20)	($4.40)	($3.60)	($6.40)	($174.00)	($3.20)	($4.40)	($1.08)	($2.10)
Adjusted Weighted Average Diluted Shares Outstanding	40.77M	1.05M	47.92M	48.34M	48.77M	1.22M	50.13M	51.38M	52.25M	51.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	($167.20)	$0.00	$0.00	$0.00	($174.00)	$0.00	$0.00	$0.00	($2.10)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	48.50M	48.81M	52.14M	49.47M	52.96M	53.81M	55.28M	55.58M	57.48M	58.03M
Normalized Net Operating Profit after Tax (NOPAT)	-458	-162	-151	-129	-133	-125	-125	-111	-37	-73
Normalized NOPAT Margin	-690.47%	-164.42%	-187.13%	-160.00%	-240.17%	-358.75%	-328.38%	-196.80%	-41.08%	-165.40%
Pre Tax Income Margin	-1,009.31%	-191.13%	-253.88%	-215.03%	-546.48%	-609.67%	-437.17%	-386.06%	-63.76%	-245.99%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-22.84	0.00	0.00	0.00	-3.90	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-18.85	0.00	0.00	0.00	-2.83	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-25.85	0.00	0.00	0.00	-3.94	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-21.85	0.00	0.00	0.00	-2.88	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.07%	-0.12%	0.00%	0.00%	-0.07%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Ginkgo Bioworks' Financials

When does Ginkgo Bioworks's fiscal year end?

According to the most recent income statement we have on file, Ginkgo Bioworks' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Ginkgo Bioworks' net income changed over the last 2 years?

Ginkgo Bioworks' net income appears to be on a downward trend, with a most recent value of -$547.03 million in 2024, falling from -$2.11 billion in 2022. The previous period was -$892.87 million in 2023. Find out what analysts predict for Ginkgo Bioworks in the coming months.

What is Ginkgo Bioworks's operating income?

Ginkgo Bioworks's total operating income in 2024 was -$559.76 million, based on the following breakdown:

Total Gross Profit: $182.50 million
Total Operating Expenses: $742.25 million

How has Ginkgo Bioworks revenue changed over the last 2 years?

Over the last 2 years, Ginkgo Bioworks' total revenue changed from $477.71 million in 2022 to $227.04 million in 2024, a change of -52.5%.

How much debt does Ginkgo Bioworks have?

Ginkgo Bioworks' total liabilities were at $661.39 million at the end of 2024, a 16.4% increase from 2023, and a 17.6% decrease since 2022.

How much cash does Ginkgo Bioworks have?

In the past 2 years, Ginkgo Bioworks' cash and equivalents has ranged from $561.57 million in 2024 to $1.32 billion in 2022, and is currently $561.57 million as of their latest financial filing in 2024.

How has Ginkgo Bioworks' book value per share changed over the last 2 years?

Over the last 2 years, Ginkgo Bioworks' book value per share changed from 0.90 in 2022 to 12.46 in 2024, a change of 1,291.9%.

Related Companies

This page (NYSE:DNA) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Financials

Frequently Asked Questions About Ginkgo Bioworks' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Financials

Annual Income Statements for Ginkgo Bioworks

Quarterly Income Statements for Ginkgo Bioworks

Annual Cash Flow Statements for Ginkgo Bioworks

Quarterly Cash Flow Statements for Ginkgo Bioworks

Annual Balance Sheets for Ginkgo Bioworks

Quarterly Balance Sheets for Ginkgo Bioworks

Annual Metrics and Ratios for Ginkgo Bioworks

Quarterly Metrics and Ratios for Ginkgo Bioworks

Frequently Asked Questions About Ginkgo Bioworks' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools